Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Thallion Pharmaceuticals has completed the recruitment and administration of the extension phase of its phase I/II clinical trial investigating its cancer drug candidate.
Subscribe to our email newsletter
In the extension phase of the study, 12 patients were treated at the highest dose, 480mg/m2/day, as determined in first portion of the trial. The phase I/II clinical trial was designed to examine the safety, pharmacologic profile and anti-tumor efficacy of ECO-4601 for the treatment of advanced cancer patients.
The completion of the clinical trial with ECO-4601 allows the company to move forward to a phase II setting where the compound will be tested in specific cancer indications, Thallion said.
Lloyd Segal, CEO of Thallion Pharmaceuticals, said: “Final data analysis of the safety and pharmacokinetic profile along with efficacy is expected to be completed and presented next quarter and will be used to design the phase II trial which we expect to initiate in the first half of 2008.”